Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gravina

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Helicobacter|June 21, 2018
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practiceRocco Maurizio Zagari, Alessandra Romiti, Enzo Ierardi, et al.
Reviews on Recent Clinical Trials|June 30, 2020
Light Alcohol Drinking and the Risk of Cancer Development: A Controversial RelationshipGiuseppe G Caprio, Desiree Picascia, Marcello Dallio, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society|January 6, 2022
Efficacy of ustekinumab in the treatment of patients with Crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life studyA Miranda, A G Gravina, A Cuomo, et al.
Gastroenterology|April 9, 2013
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistanceJavier Molina-Infante, Marco Romano, Miguel Fernandez-Bermejo, et al.
Minerva Gastroenterology|March 9, 2022
Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular diseaseGiovanni Brandimarte, Giovanni V Frajese, Stefano Bargiggia, et al.
United European Gastroenterology Journal|November 12, 2020
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practiceOlga P Nyssen, Angeles Perez-Aisa, Manuel Castro-Fernandez, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2015
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsJ P Gisbert, M Romano, A G Gravina, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 7, 2025
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)D Noviello, W Fries, A Orlando, et al.
United European Gastroenterology Journal|December 5, 2023
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori managementManuel Pabón-Carrasco, Alma Keco-Huerga, Manuel Castro-Fernández, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Helicobacter|June 21, 2018
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practiceRocco Maurizio Zagari, Alessandra Romiti, Enzo Ierardi, et al.
Reviews on Recent Clinical Trials|June 30, 2020
Light Alcohol Drinking and the Risk of Cancer Development: A Controversial RelationshipGiuseppe G Caprio, Desiree Picascia, Marcello Dallio, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society|January 6, 2022
Efficacy of ustekinumab in the treatment of patients with Crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life studyA Miranda, A G Gravina, A Cuomo, et al.
Gastroenterology|April 9, 2013
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistanceJavier Molina-Infante, Marco Romano, Miguel Fernandez-Bermejo, et al.
Minerva Gastroenterology|March 9, 2022
Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular diseaseGiovanni Brandimarte, Giovanni V Frajese, Stefano Bargiggia, et al.
United European Gastroenterology Journal|November 12, 2020
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practiceOlga P Nyssen, Angeles Perez-Aisa, Manuel Castro-Fernandez, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2015
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsJ P Gisbert, M Romano, A G Gravina, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 7, 2025
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)D Noviello, W Fries, A Orlando, et al.
United European Gastroenterology Journal|December 5, 2023
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori managementManuel Pabón-Carrasco, Alma Keco-Huerga, Manuel Castro-Fernández, et al.
Pageof 5